½ÃÀ庸°í¼­
»óǰÄÚµå
1405709

½ÀÀ± â»ó ÇǺ¹Àç : ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ°ú Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)

Moist Wound Dressings - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2024 - 2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

½ÀÀ± â»ó ÇǺ¹Àç ½ÃÀå ±Ô¸ð´Â 2024³â 45¾ï ´Þ·¯¿¡¼­ 2029³â¿¡´Â 58¾ï ´Þ·¯·Î ¼ºÀåÇϸç, ¿¹Ãø ±â°£(2024-2029³â) CAGRÀº 5.9%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Moist Wound Dressings-Market-IMG1

´ëÀ¯ÇàÀÇ ¹ß»ýÀº ½ÃÀå¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ºÀ¼â ±â°£ Áß ½ÃÀåÀº ÁÖ·Î ÀÓ»ó ¶Ç´Â º´¿ø ¹æ¹® °¨¼Ò·Î ÀÎÇØ ¾à°£ÀÇ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» º¸¾Ò½À´Ï´Ù. Àü¿°º´ ±â°£ Áß º´¿øÀÇ ´ëºÎºÐÀÇ »óó Ä¡·á ¼¾ÅÍ´Â Æó¼âµÇ¾ú°í, ´Ù¸¥ Áúº´À¸·Î ÀÎÇÑ ÀÀ±Þ »óȲÀÌ ¹ß»ýÇÏÁö ¾Ê´Â ÇÑ COVID ȯÀÚ¸¸ ¿ì¼± ¼øÀ§¸¦ Á¤Çß½À´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 4¿ù¿¡ ¹ßÇ¥µÈ NCBIÀÇ ¿¬±¸¿¡ µû¸£¸é ¸¸¼º »óó ȯÀÚ´Â °ÅÀÇ ¸ðµç ÀÇ·á ȯ°æ¿¡¼­ Ä¡·á¸¦ ¹Þ°í ÀÖ¾ú½À´Ï´Ù. °°Àº Á¤º¸¿øÀº ¶ÇÇÑ Àü¿°º´¿¡ ´ëÀÀÇϱâ À§ÇØ ÀϺΠº´¿øÀÌ »óó ¼¾Å͸¦ Æó¼âÇß´Ù°í ¹àÇû½À´Ï´Ù. ±× ÀÌÀ¯´Â ÀÌ ¼­ºñ½º¸¦ ÇʼöÀûÀÌÁö ¾ÊÀº °ÍÀ¸·Î À߸ø ºÐ·ùÇϰųª ¹æ¹®ÀÚ ¹× ¿Ü·¡ ȯÀÚÀÇ º´¿ø ºÎÁö ÃâÀÔÀ» Á¦ÇÑÇ߱⠶§¹®ÀÔ´Ï´Ù. µû¶ó¼­ ÀÌ ±â°£ Áß ½ÃÀå ¼ºÀåÀÌ ÀúÇØµÇ¾ú½À´Ï´Ù. ±×·¯³ª °¢±¹ÀÌ COVID-19¸¦ ÅëÁ¦Çϱâ À§ÇØ ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥À» Ȱ¿ëÇϱ⠽ÃÀÛÇϸ鼭 Ŭ¸®´Ð°ú º´¿øÀÇ Á¤»óÀûÀÎ ¿î¿µÀ» º¼ ¼ö ÀÖ°Ô µÇ¾ú°í, ÀÌ´Â ½ÃÀå ¼ºÀå¿¡ ±â¿©Çß½À´Ï´Ù. ÀÌó·³ º´¿ø ¹× Ŭ¸®´ÐÀÇ »óó Ä¡·á ¼¾ÅÍ¿Í »óó Ä¡·á ¼­ºñ½º Àç°³·Î ÀÎÇØ ½ÃÀåÀÌ °ßÀηÂÀ» °®±â ½ÃÀÛÇßÀ¸¸ç, ¿¹Ãø ±â°£ Áß¿¡µµ Áõ°¡ Ãß¼¼°¡ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸¸¼º ¹× ±Þ¼º »óó ¹ß»ý·ü Áõ°¡, ¸¸¼ºÁúȯ, »ç°í ¹× È­»ó »ç·Ê Áõ°¡, °í±Þ »óó °ü¸® Á¦Ç°¿¡ ´ëÇÑ ÀÎ½Ä ¹× äÅà Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù. ¿¹¸¦ µé¾î ±¹Á¦´ç´¢º´¿¬¸Í(IDF)ÀÇ 2021³â ÃֽŠÁ¤º¸¿¡ µû¸£¸é ¾à 5¾ï 3,700¸¸ ¸íÀÇ ¼ºÀÎ(20-79¼¼)ÀÌ ´ç´¢º´À» ¾Î°í ÀÖ½À´Ï´Ù. ´ç´¢º´ ȯÀÚ ¼ö´Â 2030³â±îÁö 6¾ï 4,300¸¸ ¸í, 2045³â±îÁö 7¾ï 8,300¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ 2022³â 8¿ù¿¡ ¹ßÇ¥µÈ NCBIÀÇ ¿¬±¸¿¡ µû¸£¸é 2021³â ´ç´¢º´¼º Á·ºÎ±Ë¾çÀÇ ¿¬°£ ¹ß»ý·üÀº Àü ¼¼°è¿¡¼­ 910¸¸-2,610¸¸ ¸í¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. ¶ÇÇÑ ´ç´¢º´ ȯÀÚÀÇ ¾à 15-25%°¡ ÀÏ»ý µ¿¾È ´ç´¢º´¼º Á·ºÎ ±Ë¾çÀÌ ¹ß»ýÇÑ´Ù°í ¹àÇû½À´Ï´Ù. ÇÏÀ̵å·ÎÄÝ·ÎÀÌµå µå·¹½Ì°ú °°Àº ½ÀÀ± â»ó ÇǺ¹ÀçÀº ½ÀÀ± »óó Ä¡À¯ ȯ°æÀ» À¯ÁöÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÇÏÀ̵å·ÎÄÝ·ÎÀ̵å´Â ±«»ç ¹× ¹Ú¸®µÈ Á¶Á÷ÀÇ ÀÚ°¡ ¹Ú¸®¸¦ ÃËÁøÇÏ¿© ´ç´¢º´¼º Á·ºÎ±Ë¾çÀÇ Á¶±â ȸº¹À» µ½½À´Ï´Ù. ½ÀÀ± â»ó ÇǺ¹ÀçÀº ´ç´¢º´¼º Á·ºÎ±Ë¾ç ȯÀڵ鿡°Ô ¸Å¿ì ¼±È£µÇ±â ¶§¹®¿¡ ´ç´¢º´ ¹× ´ç´¢º´¼º Á·ºÎ±Ë¾ç ȯÀÚ Áõ°¡´Â ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ 2022³â 7¿ù¿¡ ¹ßÇ¥µÈ NCBIÀÇ ¿¬±¸¿¡ µû¸£¸é Àü ¼¼°è¿¡¼­ ¼Ò¾Æ È­»óÀÇ »ó´ç ºÎºÐÀ» ¼Ò¾Æ ȯÀÚ°¡ Â÷ÁöÇϰí ÀÖÀ¸¸ç, ¼Ò¾Æ È­»ó Ä¡·á´Â ÃÖ÷´Ü ȯ°æ¿¡¼­µµ ¾î·Á¿î °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ ¿¬±¸¿¡ µû¸£¸é ¼Ò¾Æ ȯÀÚ´Â Àü ¼¼°è È­»ó ȯÀÚÀÇ °ÅÀÇ Àý¹Ý(42.0%)À» Â÷ÁöÇϸç, À¯¾Æ(1-5¼¼)°¡ ¼Ò¾Æ È­»óÀÇ °¡Àå Å« ºñÀ²À» Â÷ÁöÇÕ´Ï´Ù. ÇÏÀ̵å·Î°Ö µå·¹½Ì Àç·á´Â ±âÁ¸ Ä¡·á¹ýÀÇ ÇѰ踦 ±Øº¹ÇÏ´Â µ¶Æ¯ÇÑ Æ¯¼ºÀ» °¡Áö°í ÀÖÀ¸¹Ç·Î È­»ó »óó Ä¡À¯¸¦ ÃËÁøÇÏ´Â µ¥ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÇÏÀ̵å·Î°Ö µå·¹½Ì Àç·á´Â È­»ó »óó¸¦ µ¤°í »óÇÇÈ­¸¦ ÃËÁøÇϰí, °¨¿°°ú ±â°èÀû ¿Ü»óÀ» ¿¹¹æÇϰí, »óó¸¦ ÃËÃËÇÏ°Ô À¯ÁöÇϰí, ÅëÁõÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ È­»ó »óó Áõ°¡´Â ½ÀÀ± â»ó ÇǺ¹Àç¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄÑ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ 2022³â 5¿ù¿¡ ¹ßÇ¥µÈ NCBIÀÇ Á¶»ç ¿¬±¸¿¡ µû¸£¸é ¼±Áø±¹¿¡¼­´Â ÀÏ¹Ý Àα¸ÀÇ ¾à 1-2%°¡ ¸¸¼º »óó¸¦ ¾Î°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »óó ¹ß»ý·ü Áõ°¡´Â ½ÀÀ± â»ó ÇǺ¹Àç Àç·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ±ÞÁõ½ÃÄÑ ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±×·¯³ª °í°¡ÀÇ Ä¡·á¿Í ½Ã¼úÀÌ ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

½ÀÀ±µå·¹½Ì ½ÃÀå µ¿Çâ

´ç´¢º´¼º ±Ë¾ç ºÎ¹®ÀÌ ¿¹Ãø ±â°£ Áß °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»ó

´ç´¢º´¼º Á·ºÎ±Ë¾çÀº NCBI Á¶»ç¿¡ µû¸£¸é ´ç´¢º´ ȯÀÚÀÇ ¾à 15.0%¿¡¼­ ¹ß»ýÇÏ´Â °³¹æ¼º »óó ¶Ç´Â ±Ë¾çÀ¸·Î, ÀϹÝÀûÀ¸·Î ¹ß¹Ù´Ú¿¡ »ý±é´Ï´Ù. Á·ºÎ±Ë¾çÀº ´ç´¢º´ÀÇ ÈçÇÑ ÇÕº´ÁõÀ¸·Î ½ÄÀÌ¿ä¹ý, ¿îµ¿¿ä¹ý, Àν¶¸° Ä¡·á µîÀÇ ¹æ¹ýÀ¸·Î °ü¸®ÇÒ ¼ö ¾ø´Â ÁúȯÀÔ´Ï´Ù. ´ç´¢º´¼º Á·ºÎ ±Ë¾ç¿¡ ´ëÇÑ ½ÀÀ± â»ó ÇǺ¹ÀçÀº ÇÏÀ̵å·ÎÄÝ·ÎÀ̵å¿Í ÇÏÀ̵å·Î°ÖÀÌ ÁÖ·Î »ç¿ëµË´Ï´Ù.

´ç´¢º´ ȯÀÚ Áõ°¡¿Í ´ç´¢º´ÀÇ Àå±âÈ­·Î ÀÎÇØ ´ç´¢º´¼º Á·ºÎ±Ë¾çÀ¸·Î À̾îÁö´Â ´ç´¢º´ÀÇ Àå±âÈ­°¡ ÀÌ ºÎ¹®ÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 9¿ù¿¡ ¹ßÇ¥µÈ NCBIÀÇ ¿¬±¸¿¡ µû¸£¸é ´ç´¢º´¼º Á·ºÎ ±Ë¾çÀÇ ¿¬°£ ¹ß»ý·üÀº 2.2%À̸ç, ´ç´¢º´ ȯÀÚÀÇ Æò»ý Á·ºÎ ±Ë¾ç À§ÇèÀº ÃÖ´ë 34%¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. 1³â À̳»¿¡ ´ç´¢º´¼º Á·ºÎ±Ë¾ç(DFU)ÀÇ Àç¹ß·üÀº ÃÖ´ë 40%¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. °°Àº ÀÚ·á¿¡ µû¸£¸é Á·ºÎ±Ë¾ç ȯÀÚÀÇ 50-60%´Â ÃÖÃÊ Áø´Ü ÈÄ 5³â ÈÄ¿¡µµ »ýÁ¸ÇØ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ 2022³â 8¿ù¿¡ ¹ßÇ¥µÈ NCBIÀÇ ¿¬±¸¿¡ µû¸£¸é ´ç´¢º´¼º Á·ºÎ±Ë¾çÀº ¿¬°£ 910¸¸-2,610¸¸ °Ç¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. ´ç´¢º´ ȯÀÚÀÇ ¾à 15-25%°¡ ¾î´À ½ÃÁ¡¿¡ ´ç´¢º´¼º Á·ºÎ ±Ë¾çÀ» °æÇèÇÕ´Ï´Ù. ´ç´¢º´ ȯÀÚ Áõ°¡´Â ´ç´¢º´¼º Á·ºÎ±Ë¾ç Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 6¿ù¿¡ ¹ßÇ¥µÈ NCBIÀÇ ¿¬±¸¿¡ µû¸£¸é ´ç´¢º´¼º Á·ºÎ±Ë¾çÀÇ Æò»ý ¹ßº´ À§ÇèÀº 19%-34%À̸ç, Àü ¼¼°è ´ç´¢º´ ȯÀÚ 5¾ï ¸í Áß ÃÖ´ë 3ºÐÀÇ 1ÀÌ Æò»ý µ¿¾È ´ç´¢º´¼º Á·ºÎ±Ë¾ç¿¡ °É¸± ¼ö ÀÖ´Ù°í ÇÕ´Ï´Ù. ÀÌ Ãâó´Â ¶ÇÇÑ ´ç´¢º´ ȯÀÚÀÇ ¿¬°£ Á·ºÎ ±Ë¾ç ¹ß»ý·üÀÌ 1.9%¿¡¼­ 4.0%¿¡ ´ÞÇÑ´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌó·³ ´ç´¢º´°ú ´ç´¢º´¼º Á·ºÎ±Ë¾ç ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ Áß »ó´çÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

Moist Wound Dressings-Market-IMG2

ºÏ¹Ì°¡ ¿¹Ãø ±â°£ Áß Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î Àü¸Á

ºÏ¹Ì´Â ¿¹Ãø ±â°£ Áß Àüü ½ÀÀ± â»ó ÇǺ¹Àç ½ÃÀåÀ» Áö¹èÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¿ìÀ§´Â ´ç´¢º´, È­»ó ¹× ¼ö¼úÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ¼ö¼ú ºÎÀ§ °¨¿°(SSI) »ç·Ê°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 1¿ù¿¡ ¹ßÇ¥µÈ CDCÀÇ Á¶»ç º¸°í¼­¿¡ µû¸£¸é SSI´Â ¹Ì±¹¿¡¼­ °¡Àå ºñ¿ëÀÌ ¸¹ÀÌ µå´Â ÀÇ·á °ü·Ã °¨¿°(HAI) À¯ÇüÀ¸·Î ¿¬°£ ¾à 33¾ï ´Þ·¯ÀÇ ºñ¿ëÀÌ ¹ß»ýÇÏ¸ç ¿¬°£ 100¸¸ ÀÏ ÀÌ»óÀÇ Ãß°¡ ÀÔ¿ø ȯÀÚ¿¡°Ô ¿µÇâÀ» ¹ÌĨ´Ï´Ù°í ÇÕ´Ï´Ù. ½ÀÀ± â»ó ÇǺ¹ÀçÀº ¼ö¼ú ºÎÀ§ °¨¿°¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ¼ö¼ú ºÎÀ§ °¨¿° »ç·Ê Áõ°¡´Â ½ÀÀ± â»ó ÇǺ¹Àç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ°í ¿¹Ãø ±â°£ Áß ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ ½ÀÀ± â»ó ÇǺ¹Àç ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î´Â ÁÖ¿ä Á¦Ç° Ãâ½Ã, ½ÃÀå ÁøÃâ±â¾÷ÀÇ ÁýÁß, ÁÖ¿ä ±â¾÷ °£ Àμö ¹× Á¦ÈÞ, ¸¸¼ºÁúȯ, È­»ó, »ç°í, ¸¸¼º ¹× ±Þ¼º »óó Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹¿¡¼­´Â Àα¸ÀÇ »ó´ç¼ö°¡ ¸¸¼ºÁúȯÀÇ ¿µÇâÀ» ¹Þ°í ÀÖÀ¸¸ç, ÀÌ´Â ¸¸¼º »óóÀÇ °¡Àå ÈçÇÑ ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 3¿ù Journal of Advances in Wound Care¿¡ °ÔÀçµÈ ³í¹®¿¡ µû¸£¸é ¸¸¼º »óó´Â ¹Ì±¹ Àα¸ÀÇ ¾à 2.5%ÀÇ »îÀÇ Áú(QoL)¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌó·³ ¹Ì±¹³» »ç°í¿Í ¸¸¼º »óó°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ Áß »ó´çÇÑ ½ÃÀå ¼ºÀåÀÌ ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.

½ÀÀ± µå·¹½Ì »ê¾÷ °³¿ä

½ÀÀ±µå·¹½Ì ½ÃÀåÀº Àû´çÇÑ °æÀïÀÌ Á¸ÀçÇϸç, ¿©·¯ ´ë±â¾÷ÀÌ Á¸ÀçÇϰí ÀÖ½À´Ï´Ù. ÇöÀç ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Â ¸î¸î ´ë±â¾÷Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϱâ À§ÇØ ´Ù¸¥ ±â¾÷À» ÀμöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ »óóÀÇ ¾ÈÀü¼º°ú ºü¸¥ Ä¡À¯¸¦ À§ÇØ Ã·´Ü ±â¼úÀ» žÀçÇÑ ½ÅÁ¦Ç°À» Ãâ½ÃÇÏ´Â ±â¾÷µµ ÀÖ½À´Ï´Ù. ÇöÀç ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Â ±â¾÷À¸·Î´Â Fleming Medical Ltd, Smith &Nephew plc, Essity AB, DermaRite Industries LLC, AMERX Health Care Corporation µîÀÌ ÀÖ½À´Ï´Ù.

±âŸ ƯÀü :

  • ¿¢¼¿ Çü½ÄÀÇ ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ù°£ÀÇ ¾Ö³Î¸®½ºÆ® Áö¿ø

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç°ú ½ÃÀå Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ÃËÁø¿äÀÎ
    • ¸¸¼º â»ó ¹× ±Þ¼º â»óÀÇ ¹ß»ý·ü Áõ°¡, ¸¸¼ºÁúȯ, »ç°í, È­»óÀÇ Áõ·ÊÀÇ Áõ°¡
    • ÷´Ü â»ó Ä¡·á Á¦Ç°¿¡ ´ëÇÑ Àνİú äÅÃÀÇ Áõ°¡
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • °í¾×ÀÇ Ä¡·á¿Í ½Ã¼ú
  • Porter's Five Forces ºÐ¼®
    • ±¸¸ÅÀÚ/¼ÒºñÀÚÀÇ ±³¼··Â
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °­µµ

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • Á¦Ç°º°
    • Æû
    • ¾Ë±ä»ê¿°
    • ÇÏÀ̵å·ÎÄÝ·ÎÀ̵å
    • ÇÏÀ̵å·Î°Ö
    • ±âŸ
  • ¿ëµµº°
    • È­»ó
    • ¿åâ
    • ´ç´¢º´¼º ±Ë¾ç
    • ¼ö¼úâ
    • ±âŸ ¿ëµµ
  • ÃÖÁ¾ ¿ëµµº°
    • º´¿ø
    • ÀçÅÃÀÇ·á
    • ±âŸ ÃÖÁ¾ ¿ëµµ
  • Áö¿ªº°
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì
      • ºê¶óÁú
      • ¾Æ¸£ÇîÆ¼³ª
      • ±âŸ ³²¹Ì

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • Fleming Medical Ltd
    • Smith & Nephew plc
    • Essity AB
    • DermaRite Industries LLC
    • AMERX Health Care Corporation
    • ConvaTec Inc
    • Molnlycke Health Care AB
    • 3M
    • Integra Lifesciences
    • Coloplast Corp

Á¦7Àå ½ÃÀå ±âȸ¿Í ÇâÈÄ µ¿Çâ

KSA 24.01.23
Moist Wound Dressings - Market - IMG1

The Moist Wound Dressings Market size is expected to grow from USD 4.5 billion in 2024 to USD 5.8 billion by 2029, registering a CAGR of 5.9% during the forecast period (2024-2029).

The outbreak of the pandemic adversely impacted the market. During the lockdown, the market witnessed a slight adverse impact, primarily due to reduced clinical or hospital visits. Most wound care centers across hospitals were closed during the pandemic as priority was given to COVID patients only unless an emergency arose for other conditions. For instance, per the NCBI study published in April 2021, patients with chronic wounds were treated in virtually every healthcare setting. The same source also stated that in response to the pandemic, some hospitals closed their wound centers because they have misclassified the service as nonessential or they have limited visitors and outpatients from entering the hospital premises. Thus, market growth was hindered during this period. However, as countries started using vaccination programs to control COVID-19, the normal working of clinics and hospitals was seen, contributing to the market's growth. Thus, with the resumption of wound care centers and wound care services in hospitals and clinics, the market has started to gain traction and is expected to continue the upward trend over the forecast period.

The growing incidence of chronic and acute wounds, rising cases of chronic diseases, accidents, and burns, and rising awareness and adoption of advanced wound care products are the major drivers for the market. For instance, as per the 2021 update from the International Diabetic Federation (IDF), approximately 537.0 million adults (20-79 years) were living with diabetes. The total number of people living with diabetes is projected to rise to 643.0 million by 2030 and 783.0 million by 2045. Moreover, according to the NCBI study published in August 2022, the annual incidence of diabetic foot ulcers was between 9.1 and 26.1 million worldwide in 2021. The same source also stated that approximately 15% to 25% of patients with diabetes mellitus will develop a diabetic foot ulcer during their lifetime. Moist wound dressing such as hydrocolloid dressing helps to maintain a moist wound healing environment. It promotes autolytic debridement of necrotic and sloughing tissues, thereby allowing rapid recovery of diabetic foot ulcers. Since moist wound dressings are highly preferred for diabetic foot ulcer cases, increasing cases of diabetes and diabetic foot ulcers are expected to positively impact the market growth over the forecast period.

Furthermore, according to the NCBI study published in July 2022, children experience a large proportion of burns worldwide, and treatment of pediatric burns is challenging even in the most advanced settings. The study showed that pediatric patients account for almost half of the burns worldwide (42.0%), and young children (ages 1-5 years) account for the largest proportion of pediatric burns. Hydrogel dressings are widely used to accelerate burn wound healing as they have unique properties to overcome the limitations of existing treatment methods. Hydrogel dressings are applied to cover burn wounds, and they promote epithelialization, prevent infection and mechanical trauma, keep wounds moist, and help reduce pain. Thus, increasing cases of burn wounds are expected to propel the demand for moist wound dressings, propelling the market growth. Moreover, according to the NCBI research study published in May 2022, around 1% to 2% of the general population in developed countries suffers from chronic wounds. This increase in the incidence of wounds is expected to surge the demand for moist wound dressing, thereby boosting the market growth over the forecast period.

However, highly expensive treatments and procedures will likely hinder market growth over the forecast period.

Moist Wound Dressings Market Trends

Diabetic Ulcers Segment is Expected to Hold the Largest Share Over the Forecast Period

A diabetic foot ulcer is an open wound or sore that occurs in approximately 15.0% of patients with diabetes and is commonly located on the bottom of the foot, as per the NCBI research study. Foot ulcers are a common complication of diabetes that is not being managed through methods such as diet, exercise, and insulin treatment. Hydrocolloid and hydrogel dressings are the major moist wound dressings for diabetic foot ulcers.

The increasing cases of diabetes and prolonged diabetes leading to diabetic foot ulcers are the major drivers for the segment. For instance, according to the NCBI study published in September 2021, the annual incidence of diabetic foot ulceration was 2.2%, and the lifetime risk of foot ulceration among people with diabetes was up to 34%. Within a year, the recurrence rate of diabetic foot ulcers (DFU) can reach up to 40%. The same source also stated that 50-60% of foot ulcer patients survive five years after their initial presentation. Furthermore, according to the NCBI study published in August 2022, there were 9.1 to 26.1 million diabetic foot ulcers yearly. Approximately 15% to 25% of people with diabetes mellitus have experienced a diabetic foot ulcer at some point. The increasing cases of diabetes are also contributing to the increasing number of diabetic foot ulcer cases. For instance, according to the NCBI research study published in June 2021, the lifetime risk of developing a diabetic foot ulcer is between 19% and 34%, and up to one-third of the half a billion people with diabetes worldwide will develop a diabetic foot ulcer in their lifetime. The same source also reported that the annual incidence of foot ulceration is between 1.9% and 4.0% of the diabetic population. Thus, owing to increasing cases of diabetes and diabetic foot ulcers, considerable segment growth is anticipated over the forecast period.

Moist Wound Dressings - Market - IMG2

North America is Expected to Witness Significant Share Over the Forecast Period

North America is expected to dominate the overall moist wound dressings market throughout the forecast period. The dominance is due to the rise in the prevalence of diabetes, burns, and surgeries, resulting in rising Surgical Site Infection (SSI) cases in the region. For instance, according to the CDC survey report published in January 2021, SSI is the most expensive healthcare-associated infection (HAI) type in the US, which accounted for an estimated annual cost of about USD 3.3 billion and affects more than 1.0 million additional inpatient days annually. The moist wound dressing is widely used in cases of surgical site infection. Thus, increasing cases of surgical site infection is expected to propel the demand for moist wound dressing, thereby surging the market growth in the region over the forecast period.

Key product launches, high concentration of market players or manufacturer's presence, and acquisition & partnerships among major players, and increasing cases of chronic diseases, burns, accidents, and chronic and acute wounds in the United States are some of the factors driving the growth of the moist wound dressings market in the country. For instance, much of the United States population is affected by chronic diseases, the most common cause of chronic wounds. For instance, a March 2021 article published in the Journal of Advances in Wound Care indicated that chronic wounds impact the quality of life (QoL) of nearly 2.5% of the United States population. Thus, owing to the country's increasing number of accident cases and chronic wounds, significant market growth is expected over the forecast period.

Moist Wound Dressings Industry Overview

The moist wound dressings market is moderately competitive and has several major players. A few of the major players currently dominating the market are making acquisitions with other companies to consolidate their global market positions. Others are launching new products with advanced technologies to enhance the safety and quicker healing of wounds. Some of the companies that are currently dominating the market are Fleming Medical Ltd, Smith & Nephew plc, Essity AB, DermaRite Industries LLC, and AMERX Health Care Corporation, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Chronic and Acute Wounds, Rising Cases of Chronic Diseases, Accidents, and Burns
    • 4.2.2 Rising Awareness and Adoption of Advanced Wound Care Product
  • 4.3 Market Restraints
    • 4.3.1 Highly Expensive Treatment and Procedures
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Foam
    • 5.1.2 Alginate
    • 5.1.3 Hydrocolloid
    • 5.1.4 Hydrogel
    • 5.1.5 Others
  • 5.2 By Application
    • 5.2.1 Burn Wounds
    • 5.2.2 Pressure Ulcer
    • 5.2.3 Diabetic Ulcer
    • 5.2.4 Surgical Wounds
    • 5.2.5 Other Applications
  • 5.3 By End-Use
    • 5.3.1 Hospitals
    • 5.3.2 Homecare
    • 5.3.3 Other End-Uses
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Fleming Medical Ltd
    • 6.1.2 Smith & Nephew plc
    • 6.1.3 Essity AB
    • 6.1.4 DermaRite Industries LLC
    • 6.1.5 AMERX Health Care Corporation
    • 6.1.6 ConvaTec Inc
    • 6.1.7 Molnlycke Health Care AB
    • 6.1.8 3M
    • 6.1.9 Integra Lifesciences
    • 6.1.10 Coloplast Corp

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦